Metabolomic Markers of Fatigue in Inflammatory Bowel Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04191707

Enrollment

Registered

2019-12-10

Start date

2013-11-01

Completion date

2019-12-01

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Fatigue, Inflammatory Bowel Disease, Ulcerative Colitis

Brief summary

Fatigue is a common symptom and a leading concern in patients with inflammatory bowel disease (IBD) and often persists despite clinical and endoscopic remission. This study evaluates the metabolomic profile of fatigued patients with IBD.

Detailed description

To date, there is only one non-published study using metabolomics in quiescent IBD patients with and without fatigue. The investogators designed this study to examine if there are metabolomics factors associated to fatigue in IBD patients. This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion. The investigators recorded demographic data, IBD classification according to the Montreal classification, and history of drug administration. In addition, clinical activity of the disease was measured using the Harvey-Bradshaw score for Crohn's disease (CD) and the modified Mayo score for ulcerative colitis (UC). The Functional Assessment of chronic Illness Therapy-Fatigue (FACIT-F) was used to assess fatigue.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Inflammatory bowel disease diagnosed at least 6 months before the study (diagnosed by clinical, laboratory , endoscopic and histological criteria) .

Exclusion criteria

* Age below 18 years. * Refusal to give written informed consent prior to participation * Active infection at the time of inclusion. * Concomitant diseases not related to IBD (e.g., cancer, heart disease, pulmonary disease) that might contribute to the presence or the severity of fatigue. * Active flare of IBD in the last 3 months.

Design outcomes

Primary

Measure	Time frame	Description
changes in metabolomic profile	1 year	The metabolic profile consisted in 75 metabolites that were measured

Outcome results